Eurofins

Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests. 

An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.

The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. 

The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.

The lab was opened earlier this year as the company's central genomics lab in North America, offering various genomic services such as DNA sequencing.

The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.

Living DNA can break down the origins of a customer’s ancestry into 21 distinct regions within Britain alone, as well as across 80 different worldwide populations.

The company's subsidiary Viracor-IBT can now run the real time, reverse transcriptase-PCR assay for patients meeting clinical or epidemiological criteria for Zika.

The combined company, which will retain the Eurofins BioDiagnostics name, will offer a range of analytical testing services to the ag-bio market.

Pages

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.